Hyperlipidemia patient Brand Pitavastatin VS Generic Pitavastatin Cost-
Conditions
Interventions
The patient was treated with pitavastatin and treatment regimen had been switched from brand pitavastatin to generic pitavastatin. In each treatment had undergone at least 6 weeks and had LDL-
C level within 3 months after start pitavatatin.
Other
The patient was treated with pitavastatin
Sponsors
Faculty of Medicine, Chiang Mai University
Nichi-
Iko (Thailand) Co.,
Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Male or female ≥ 18 years of age (2) Have hypercholesterolemia (3) Treatment regimen had been switched from brand pitavastatin to generic pitavastatin. In each treatment had undergone at least 6 weeks and had LDL-C level within 3 months after start pitavatatin. (4) Stable dose of other lipid management agent
Exclusion criteria
Exclusion criteria: (1) Significant human immunodeficiency virus (HIV) (2) History of malignancy with a life expectancy less than 1 year (3) History of chronic kidney disease or GFR ≤ 30 mL/min/1.73 m² (4) Liver disease or serum aspartate aminotransferase (AST) and/ or alanine aminotransferase (ALT) > 3x upper limit of normal (ULN)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The cost-effectiveness ratio (CER-TA) target achievement rate 3 months Cost of Pitavastatin | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL-C result 3 months LDL value,Adverse event rate 12 months Number of adverse event | — |
Countries
Thailand
Contacts
Public ContactArintaya Phrommintikul
Faculty of Medicine, Chiang Mai University
Outcome results
None listed